Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma

被引:92
|
作者
Blechacz, Boris
Splinter, Patrick L.
Greiner, Suzanne
Myers, Rae
Peng, Kah-Whye
Federspiel, Mark J.
Russell, Stephen J.
LaRusso, Nicholas F.
机构
[1] Mayo Clin, Ctr Basic Res Digest Dis, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[2] Mayo Clin, Mol Med Program, Rochester, MN 55905 USA
关键词
D O I
10.1002/hep.21437
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The oncolytic measles virus Edmonston strain (MV-Edm), a nonpathogenic virus targeting cells expressing abundant CD46, selectively destroys neoplastic tissue. Clinical development of Mv-Edm would benefit from noninvasive monitoring strategies to determine the speed and extent of the spread of the virus in treated patients and the location of virus-infected cells. We evaluated recombinant NW-Edrn expressing carcinoembryonic antigen (CEA) or the human sodium iodide symporter (hNIS) for oncolytic potential in hepatocellular carcinoma (HCC) and efficiency in tracking viruses in vivo by noninvasive monitoring. CD46 expression in human HCC and primary hepatocytes was assessed by flow cytometry and immunohistochemistry. Infectivity, syncytium formation, and cytotoxicity of recombinant MV-Edm in HCC cell lines were evaluated by fluorescence microscopy, crystal violet staining, and die NITS assay. Transgene expression in HCC cell lines after infection with recombinant NW-Edm in vitro and in vivo was assessed by CEA concentration, I-125-uptake, and I-123-imaging studies. Toxicology studies were performed in Ifnar(KO) X CD46 transgenic mice. The CD46 receptor was highly expressed in HCC compared to nonmalignant hepatic tissue. Recombinant MV-Edm efficiently infected HCC cell lines, resulting in extensive syncytium formation followed by cell death. Transduction of HCC cell lines and subcutaneous HCC xenografts with recombinant MV-Edm resulted in high-level expression of transgenes in vitro and in vivo. MV-Edm was nontoxic in susceptible mice. Intratumoral and intravenous therapy with recombinant MV-Edm resulted in inhibition of tumor growth and prolongation of survival with complete tumor regression in up to one third of animals. In conclusion, engineered NW-Edrn may be a potent and novel cancer gene therapy system for HCC. MV-Edm expressing CEA or hNIS elicited oncolytic effects in human HCC cell lines in vitro and in vivo, enabling the spread of the virus to be monitored in a noninvasive manner.
引用
收藏
页码:1465 / 1477
页数:13
相关论文
共 50 条
  • [21] Oncolytic measles virus strains as novel anticancer agents
    Msaouel, Pavlos
    Opyrchal, Mateusz
    Musibay, Evidio Domingo
    Galanis, Evanthia
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (04) : 483 - 502
  • [22] Engineered measles virus Edmonston strain used as a novel oncolytic viral system against human neuroblastoma through a CD46 and nectin 4-independent pathway
    Zhang, Shu-Cheng
    Cai, Wei-Song
    Zhang, Yao
    Jiang, Kai-Lei
    Zhang, Ke-Ren
    Wang, Wei-Lin
    CANCER LETTERS, 2012, 325 (02) : 227 - 237
  • [23] Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma
    Lili Deng
    Xue Yang
    Yuedi Ding
    Jun Fan
    Ying Peng
    Dong Xu
    Biao Huang
    Zhigang Hu
    Virology Journal, 19
  • [24] Oncolytic therapy with vaccinia virus carrying IL-24 for hepatocellular carcinoma
    Deng, Lili
    Yang, Xue
    Ding, Yuedi
    Fan, Jun
    Peng, Ying
    Xu, Dong
    Huang, Biao
    Hu, Zhigang
    VIROLOGY JOURNAL, 2022, 19 (01)
  • [25] Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: An overview
    Msaouel, Pavlos
    Dispenzieri, Angela
    Galanis, Evanthia
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2009, 11 (01) : 43 - 53
  • [26] Immune checkpoint blockade enhances oncolytic Measles virus therapy
    Engeland, C. E.
    Veinalde, R.
    Grossardt, C.
    Shevchenko, I.
    Umansky, V.
    Nettelbeck, D. M.
    Jaeger, D.
    von Kalle, C.
    Ungerechts, G.
    HUMAN GENE THERAPY, 2014, 25 (11) : A47 - A47
  • [27] A Novel Armed Oncolytic Measles Vaccine Virus for the Treatment of Cholangiocarcinoma
    Lange, Sebastian
    Lampe, Johanna
    Bossow, Sascha
    Zimmermann, Martina
    Neubert, Wolfgang
    Bitzer, Michael
    Lauer, Ulrich M.
    HUMAN GENE THERAPY, 2013, 24 (05) : 554 - 564
  • [28] A novel strategy of oncotherapy using a recombinant oncolytic measles virus
    Kai, Chieko
    Sugiyama, Takaaki
    Fujiyuki, Tomoko
    Yoneda, Misako
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S131 - S131
  • [29] Immune Checkpoint Modulation Enhances Oncolytic Measles Virus Therapy
    Engeland, Christine E.
    Veinalde, Rueta
    Grossardt, Christian
    Jaeger, Dirk
    von Kalle, Christof
    Ungerechts, Guy
    MOLECULAR THERAPY, 2015, 23 : S247 - S248
  • [30] Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
    Yoo, So Young
    Badrinath, Narayanasamy
    Woo, Hyun Young
    Heo, Jeong
    MEDIATORS OF INFLAMMATION, 2017, 2017